Skip to content

Phase I trial, BDD code: BDD22306

Phase I trial, BDD code: BDD22306

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN79577836
Enrollment
15
Registered
2023-10-10
Start date
2023-09-07
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended. Not Specified

Interventions

Sponsors

Contera Pharma
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

Exclusion criteria

Exclusion criteria: The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

Design outcomes

Primary

MeasureTime frame
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

Secondary

MeasureTime frame
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

Countries

Scotland, United Kingdom

Contacts

Public ContactLyn Corry
lyn.corry@bddpharma.com+44 141 552 8791

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 30, 2026